Evidence map›Paper›PMID 35216497›Full record

ArticleInternational journal of molecular sciences2022

Common Molecular Targets of a Quinolone Based Bumped Kinase Inhibitor in

Joachim Müller, Nicoleta Anghel, Dennis Imhof, Kai Hänggeli, Anne-Christine Uldry, Sophie Braga-Lagache, Manfred Heller, Kayode K Ojo, Luis-Miguel Ortega-Mora, Wesley C Van Voorhis and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Microorganisms · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Treatment with BKI-1748 afterAntimicrobial agents and chemotherapy · 2025
    Article
  7. Transient Adaptation ofInternational journal of molecular sciences · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Expert opinion on therapeutic targets
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Joachim MüllerInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Länggass-Strasse 122, 3012 Bern, Switzerland.ORCID 0000-0001-8189-9270
Nicoleta AnghelInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Länggass-Strasse 122, 3012 Bern, Switzerland.
Dennis ImhofInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Länggass-Strasse 122, 3012 Bern, Switzerland.
Kai HänggeliInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Länggass-Strasse 122, 3012 Bern, Switzerland.
Anne-Christine UldryProteomics and Mass Spectrometry Core Facility, Department for BioMedical Research (DBMR), University of Bern, 3008 Bern, Switzerland.ORCID 0000-0003-2820-0277
Sophie Braga-LagacheProteomics and Mass Spectrometry Core Facility, Department for BioMedical Research (DBMR), University of Bern, 3008 Bern, Switzerland.
Manfred HellerProteomics and Mass Spectrometry Core Facility, Department for BioMedical Research (DBMR), University of Bern, 3008 Bern, Switzerland.ORCID 0000-0002-6364-7325
Kayode K OjoCenter for Emerging and Re-Emerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA.ORCID 0000-0002-2007-2170
Luis-Miguel Ortega-MoraSALUVET, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0002-4986-6783
Wesley C Van VoorhisCenter for Emerging and Re-Emerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA.
Andrew HemphillInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Länggass-Strasse 122, 3012 Bern, Switzerland.ORCID 0000-0002-0622-2128
University of Bern · CHUniversity of Washington · USUniversidad Complutense de Madrid · ES

Funding

Optimization of Lead BKIs for Cryptosporidiosis TherapyR01AI155412 · NIAID · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2021 to 2025
$4.1M
Bumped-Kinase Inhibitor Drug Development for ToxoplasmosisR01HD102487 · NICHD · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2021 to 2025
$3.3M
NIAID NIH HHS R01 AI155412NICHD NIH HHS R01 HD102487NIH HHS 1R01AI155412-01 and R01HD102487Swiss National Science Foundation 310030_184662
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntiprotozoal AgentsCells, CulturedNeosporaProtein Kinase InhibitorsQuinolinesQuinolonesZebrafishAntiprotozoal AgentsProtein Kinase InhibitorsquinolineQuinolinesQuinolonesaffinity chromatographybinding proteinsproteomicsside effectssplicing

Identifiers

PMID35216497
PMCPMC8879773
OpenAlexW4213276838

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.